Format

Send to

Choose Destination
Cancer Res. 2015 Jan 15;75(2):264-9. doi: 10.1158/0008-5472.CAN-14-1008. Epub 2014 Dec 8.

Whole-exome sequencing reveals frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1 in malignant pleural mesothelioma.

Author information

1
Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts.
2
Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York.
3
Genome Technology Center, NYU Langone Medical Center, New York, New York.
4
University of Hawaii Cancer Center, Honolulu, Hawaii.
5
Broad Institute of Harvard and MIT, Cambridge, Massachusetts.
6
Broad Institute of Harvard and MIT, Cambridge, Massachusetts. Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts.
7
Department of Cardiothoracic Surgery, NYU Langone Medical Center, New York, New York. Harvey.Pass@nyumc.org.

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive neoplasm associated with asbestos exposure. Although previous studies based on candidate gene approaches have identified important common somatic mutations in MPM, these studies have focused on small sets of genes and have provided a limited view of the genetic alterations underlying this disease. Here, we performed whole-exome sequencing on DNA from 22 MPMs and matched blood samples, and identified 517 somatic mutations across 490 mutated genes. Integrative analysis of mutations and somatic copy-number alterations revealed frequent genetic alterations in BAP1, NF2, CDKN2A, and CUL1. Our study presents the first unbiased view of the genomic basis of MPM.

PMID:
25488749
DOI:
10.1158/0008-5472.CAN-14-1008
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center